Recursion Pharmaceuticals, Inc. (RXRX)

Recursion Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	743.29	594.35	391.57	549.91	285.12
Short-Term Investments	-	-	-	-	231.45
Cash & Short-Term Investments	743.29	594.35	391.57	549.91	516.56
Cash Growth	25.06%	51.79%	-28.79%	6.46%	97.07%
Accounts Receivable	-	-	-	-	0.03
Other Receivables	24.65	49.17	3.09	2.75	9.06
Receivables	24.65	49.17	3.09	2.75	9.09
Prepaid Expenses	11.74	29.6	-	-	-
Restricted Cash	4.59	3.05	3.23	1.28	1.55
Other Current Assets	28.57	38.11	40.25	15.87	7.51
Total Current Assets	812.85	714.27	438.14	569.81	534.72
Property, Plant & Equipment	169.48	233.21	120.17	121.45	64.73
Long-Term Investments	4.4	-	-	-	-
Goodwill	162.16	148.87	52.06	0.8	0.8
Other Intangible Assets	309.9	335.86	36.44	1.31	1.39
Long-Term Deferred Tax Assets	0.96	1.93	-	-	-
Other Long-Term Assets	14.39	14.45	6.89	7.92	8.72
Total Assets	1,474	1,449	653.7	701.29	610.35
Accounts Payable	18.12	21.61	3.95	4.59	2.82
Accrued Expenses	69.53	80.28	41.76	30.29	27.67
Current Portion of Long-Term Debt	0.12	0.11	0.04	0.1	0.09
Current Portion of Leases	21.63	22.11	6.12	5.95	-
Current Unearned Revenue	37.61	61.77	36.43	56.73	10
Other Current Liabilities	0.7	1.59	4.87	2.62	6.08
Total Current Liabilities	147.71	187.47	93.17	100.27	46.66
Long-Term Debt	0.19	0.68	1.1	0.54	0.63
Long-Term Leases	56.02	85.59	43.41	44.42	-
Long-Term Unearned Revenue	114.01	118.77	51.24	70.26	6.67
Long-Term Deferred Tax Liabilities	23.26	16.58	1.34	-	-
Other Long-Term Liabilities	2.08	4.73	-	-	13.45
Total Liabilities	343.27	413.82	190.26	215.48	67.41
Common Stock	0.01	0	0	0	0
Additional Paid-In Capital	3,170	2,474	1,431	1,125	943.14
Retained Earnings	-2,076	-1,431	-967.62	-639.56	-400.08
Comprehensive Income & Other	36.72	-7.64	-	-	-0.13
Total Common Equity	1,131	1,035	463.44	485.81	542.94
Shareholders' Equity	1,131	1,035	463.44	485.81	542.94
Total Liabilities & Equity	1,474	1,449	653.7	701.29	610.35
Total Debt	77.97	108.49	50.67	51.01	0.72
Net Cash (Debt)	665.33	485.86	340.89	498.91	515.84
Net Cash Growth	36.94%	42.52%	-31.67%	-3.28%	106.63%
Net Cash Per Share	1.49	1.77	1.64	2.84	4.12
Filing Date Shares Outstanding	527.4	401.99	234.65	191.23	170.77
Total Common Shares Outstanding	528.18	396.8	234.27	191.02	170.27
Working Capital	665.14	526.8	344.97	469.55	488.06
Book Value Per Share	2.14	2.61	1.98	2.54	3.19
Tangible Book Value	658.8	550.05	374.94	483.7	540.75
Tangible Book Value Per Share	1.25	1.39	1.60	2.53	3.18
Machinery	121.86	128.29	82.22	67.69	53.08
Construction In Progress	0.51	2.71	3.23	8.75	16.45
Leasehold Improvements	70.78	72.73	45.93	41.87	13.94

Updated Feb 25, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q